-+ 0.00%
-+ 0.00%
-+ 0.00%

UroGen Pharma: Q4 Earnings Insights

Benzinga·03/02/2026 13:02:06
Listen to the news

The Q4 earnings report for UroGen Pharma (NASDAQ:URGN) was released on Monday, March 2, 2026 at 08:00 AM.

Here's what investors need to know about the latest announcement.

Earnings

UroGen Pharma beat estimated earnings by 5.26%, reporting an EPS of $-0.54 versus an estimate of $-0.57.

Revenue was up $13.27 million from the same period last year.

Earnings History Overview

The company beat on EPS by $0.01 in the previous quarter, leading to a 1.27% drop share price change the next day.

Here's a look at UroGen Pharma's past performance:

Quarter Q3 2025 Q2 2025 Q1 2025 Q4 2024
EPS Estimate -0.70 -0.83 -0.80 -0.72
EPS Actual -0.69 -1.05 -0.92 -0.80
Revenue Estimate 31.87M 23.66M 22.70M 25.25M
Revenue Actual 27.50M 24.21M 20.25M 24.57M

To track all earnings releases for UroGen Pharma visit their earnings calendar here.

This article was generated by Benzinga's automated content engine and reviewed by an editor.